Ikena Oncology Competitors

Ikena Oncology (NASDAQ:IKNA) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Kymera Therapeutics, as provided by MarketBeat.

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Kymera Therapeutics has a consensus target price of $56.00, suggesting a potential upside of 25.73%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 50.6% of Kymera Therapeutics shares are owned by institutional investors. 23.3% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Kymera Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ikena Oncology and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Ikena Oncology has higher earnings, but lower revenue than Kymera Therapeutics.

Ikena Oncology (NASDAQ:IKNA) and Translate Bio (NASDAQ:TBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Translate Bio, as provided by MarketBeat.

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Translate Bio has a consensus target price of $25.80, suggesting a potential upside of 14.72%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Translate Bio.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 88.7% of Translate Bio shares are owned by institutional investors. 9.4% of Translate Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Translate Bio's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ikena Oncology and Translate Bio's revenue, earnings per share (EPS) and valuation.

Ikena Oncology has higher earnings, but lower revenue than Translate Bio.

Summary

Ikena Oncology beats Translate Bio on 5 of the 9 factors compared between the two stocks.

Ikena Oncology (NASDAQ:IKNA) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Cortexyme, as provided by MarketBeat.

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Cortexyme has a consensus target price of $43.3333, suggesting a potential downside of 24.12%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Cortexyme.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 62.6% of Cortexyme shares are owned by institutional investors. 20.2% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Cortexyme's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ikena Oncology and Cortexyme's revenue, earnings per share (EPS) and valuation.

Summary

Ikena Oncology beats Cortexyme on 4 of the 6 factors compared between the two stocks.

Ikena Oncology (NASDAQ:IKNA) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Replimune Group, as provided by MarketBeat.

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Replimune Group has a consensus target price of $56.00, suggesting a potential upside of 55.38%. Given Ikena Oncology's higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Replimune Group.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 73.6% of Replimune Group shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Replimune Group's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ikena Oncology and Replimune Group's revenue, earnings per share (EPS) and valuation.

Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Sangamo Therapeutics, as provided by MarketBeat.

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Sangamo Therapeutics has a consensus target price of $22.40, suggesting a potential upside of 92.77%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Sangamo Therapeutics.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 55.3% of Sangamo Therapeutics shares are owned by institutional investors. 2.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Sangamo Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ikena Oncology and Sangamo Therapeutics' revenue, earnings per share (EPS) and valuation.

Ikena Oncology has higher earnings, but lower revenue than Sangamo Therapeutics.

Summary

Ikena Oncology beats Sangamo Therapeutics on 6 of the 9 factors compared between the two stocks.

Ikena Oncology (NASDAQ:IKNA) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Ikena Oncology and Alector, as provided by MarketBeat.

Ikena Oncology currently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Alector has a consensus target price of $34.40, suggesting a potential upside of 64.91%. Given Ikena Oncology's higher possible upside, research analysts plainly believe Ikena Oncology is more favorable than Alector.

Insider and Institutional Ownership

55.9% of Ikena Oncology shares are held by institutional investors. Comparatively, 57.6% of Alector shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Alector's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Ikena Oncology and Alector's revenue, earnings per share (EPS) and valuation.

Ikena Oncology has higher earnings, but lower revenue than Alector.